Weight-loss drugs show signs of slowing biological aging, say drugmakers
AI-rewritten: This is a summary of an article from MIT Technology Review, rewritten by AI (Qwen, running locally) to make it easier to read. The facts come from the original article – read it for the full story.
Drugmakers Eli Lilly and Novo Nordisk reported that patients taking their weight-loss medications appear to age slower than those on placebo. They used molecular "aging clocks" to measure this effect, which track biological age by analyzing DNA changes or protein levels in the body. Overall, Novo Nordisk found a reduction of about two to three years in biological age for overweight or diabetic patients using GLP-1 drugs like semaglutide (Ozempic and Wegovy). Eli Lilly’s research on tirzepatide (Mounjaro and Zepbound) showed similar results with epigenetic clocks that count accumulated DNA changes.